心室辅助装置治疗中的照护缺口扩大
该研究利用STS Intermacs和Pedimacs注册数据,分析2012年9月至2021年12月植入耐久性心室辅助装置的患者,发现HVAD在年轻成人中的生存率优于年长成人,HM3在年轻成人中生存率优于HVAD,但儿童患者中未见此差异,HVAD撤出可能使部分儿童患者失去体内植入支持的选择。
要点
- 年轻成人(<40岁)中HVAD 1年生存率88.8%,优于>40岁成人的79.4%(p<0.0001)。
- 年轻成人中HM3 1年生存率94.4%,优于HVAD的88.8%(p=0.0025)。
- 儿童患者中HVAD与HM3生存率无显著差异(83.7% vs 87.3%,p=0.21)。
核心结论
- HVAD撤出可能导致年轻患者的照护缺口,其生存结局与年长成人不一致。
- HM3可部分填补该缺口且生存良好,但部分儿童患者将无法获得体内植入支持,尽管Berlin Heart EXCOR结局尚可,却无法出院回家。
- 未来器械可用性变更应考虑到使用该器械的不同患者群体,以避免意外导致的可及性不平等。
研究设计与样本
- 基于STS Intermacs和Pedimacs注册库,纳入2012年9月至2021年12月间耐久性VAD植入患者。
- Intermacs中年轻成人定义为<40岁,排除孤立性右心室辅助装置(RVAD)或作为destination therapy(DT)植入者。
- 采用Kaplan-Meier和竞争结局曲线进行生存分析,报告1年生存率。
主要发现
- Intermacs年轻成人队列n=1226(HVAD 818,HM3 408),中位年龄32.07(26.66-36.27)岁,体重83.2(68-104.2)kg,92.2%为心肌病。
- Pedimacs队列668例,中位年龄9.47(1.82-14.23)岁,体重27.2(10-57.05)kg,70.5%为心肌病,装置包括HVAD(n=326)、Berlin EXCOR(n=277)、HM3(n=65)。
- 成人中HVAD生存率因年龄而异,年轻成人优于>40岁成人(1年88.8% vs 79.4%,p<0.0001)。
- 年轻成人1年生存率优于Pedimacs患者(88.9% vs 83.7%,p=0.0002),但竞争事件分析中死亡率相似(9.2% vs 9.6%,p=0.1),Pedimacs 1年移植比例更高(74% vs 31.3%,p<0.0001)。
- 年轻成人中HVAD与HM3生存率不同(88.8% vs 94.4%,p=0.0025),儿童中未见此差异(83.7% vs 87.3%,p=0.21),包括体重≥25 kg者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The removal of the HeartWare ventricular assist device (HVAD) due to pump malfunctions and inferior outcomes compared to HeartMate 3 (HM3) in adults has created a care gap for younger patients. It is unclear if the reported HVAD survival differs by age and if the initial experience with HM3 can bridge the gap. METHODS: Using the Society of Thoracic Surgeons (STS) Intermacs and Pedimacs registries, durable ventricular assist device (VAD) implants between September 2012 and December 2021 were identified. Young adults (YA) were defined as <40 years old in Intermacs. Patients were excluded if they had an isolated right VAD (RVAD) or were implanted as destination therapy (DT). Survival analysis by Kaplan-Meier (KM) and competing outcomes curves was performed, and 1-year survival is reported. RESULTS: The Intermacs cohort consisted of YA (n = 1226; HVAD 818; HM3 408) with a median age of YA of 32.07 (26.66-36.27) years and weight (wt) of 83.2 (68-104.2) kg. Most had cardiomyopathy (CM) (92.2%). The Pedimacs cohort was 668 patients (median age 9.47 [1.82-14.23] years, wt 27.2 [10-57.05] kg), and most also had CM (70.5%). Device breakdown included HVAD (n = 326), Berlin EXCOR (n = 277), and HM3 (n = 65). HVAD survival differed by age in adults, with YA fairing better than adults >40 years old (88.8% vs 79.4% at 1 year, p < 0.0001). YA survival was also better compared to Pedimacs patient (88.9% vs 83.7%, p = 0.0002), but when competing events were analyzed, mortality was similar to YA (9.2% vs 9.6%, p = 0.1) with a higher proportion of patient undergoing transplant at 1 year in Pedimacs (74% vs 31.3%, p < 0.0001). Survival by device differed between HVAD and HM3 in YA (88.8% vs 94.4%, p = 0.0025). This difference in device survival was not seen in all children (83.7% vs 87.3%, p = 0.21), including those ≥25 kg. Adverse event profiles also differed across the groups with adults seeing less adverse events with the HM3, but the same was not found (including stroke) in the pediatric cohort. Survival outcomes for patients between 10 and 25 kg were similar with the HVAD compared to the Berlin Heart EXCOR (p = 0.4290), with similarities in stroke risk. CONCLUSION: The removal of the HVAD device may result in a care gap in younger patient whose survival outcomes do not mirror that of older adults. The HM3 can fill a portion of this gap with good survival, but there remains a subset of pediatric patients that, based on initial HM3 use, will no longer have access to intracorporeal support and therefore, despite reasonable outcomes with the Berlin Heart EXCOR, will not be able to be discharged home. Lastly, it is essential that future changes to the availability of devices take into account the various patient populations that utilize the device to avoid unintended consequences of access inequality.
引用
- Conway J, Amdani S, Morales DLS, et al. Widening care gap in VAD therapy. J Heart Lung Transplant. 2023. PMID: 37591455. doi:10.1016/j.healun.2023.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。